Assessing prescription medications for priority regulatory review

Regulatory Toxicology and Pharmacology

Volumn 42, Issue 1, 2005, Pages 70-76

  Rawson, Nigel S B ^a,b  

^a Center for Health Care Policy and Evaluation   (United States)

^b GLAXOSMITHKLINE   (Canada)

Author keywords

Canada; Clinical significance; Priority review; United States

Indexed keywords

4 METHYLPYRAZOLE; ABACAVIR; ABCIXIMAB; ALITRETINOIN; AMIFOSTINE; AMINOLEVULINIC ACID; AMLEXANOX; AMPRENAVIR; ANAGRELIDE; ANASTROZOLE; ARGATROBAN; ASPARAGINASE MACROGOL; ATORVASTATIN; BASILIXIMAB; BECAPLERMIN; BENZOPORPHYRIN DERIVATIVE; BETA1 INTERFERON; BOSENTAN; BRIMONIDINE; BRINZOLAMIDE; CABERGOLINE; CANDESARTAN; CAPECITABINE; CASPOFUNGIN; CEFDINIR; CELECOXIB; CIDOFOVIR; CITALOPRAM; CLOPIDOGREL; CONSENSUS INTERFERON; DACLIZUMAB; DALFOPRISTIN PLUS QUINUPRISTIN; DELAVIRDINE; DIRITHROMYCIN; DOLASETRON MESILATE; DONEPEZIL; DORZOLAMIDE; DOXERCALCIFEROL; EFAVIRENZ; EMEDASTINE; ENTACAPONE; EPROSARTAN; EPTIFIBATIDE; ETANERCEPT; ETHYLENEDIAMINE TETRAKIS(METHYLENEPHOSPHONIC ACID); EXEMESTANE; FONDAPARINUX; FORMOTEROL; FOSFOMYCIN; FOSPHENYTOIN SODIUM; GALANTAMINE; GATIFLOXACIN; GEMCITABINE; GLATIRAMER; HEPATITIS A VACCINE; IBUTILIDE; IMATINIB; IMIGLUCERASE; IMIQUIMOD; INDINAVIR; INFLIXIMAB; IRBESARTAN; IRINOTECAN; LATANOPROST; LEFLUNOMIDE; LEPIRUDIN; LETROZOLE; LEVOFLOXACIN; LINEZOLID; LIPOPROTEIN OSPA; MELOXICAM; MEROPENEM; MIGLITOL; MIRTAZAPINE; MODAFINIL; MONTELUKAST; MOXIFLOXACIN; NALMEFENE; NARATRIPTAN; NATEGLINIDE; NELFINAVIR; NEVIRAPINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OLANZAPINE; OLAPATADINE; OSELTAMIVIR; OXCARBAZEPINE; PALIVIZUMAB; PANTOPRAZOLE; PEGINTERFERON ALPHA2B; PENCICLOVIR; PIOGLITAZONE; PNEUMOCOCCAL 7 VALENT VACCINE; PRAMIPEXOLE; PROSTACYCLIN; QUETIAPINE; RABEPRAZOLE; RALOXIFENE; RAPAMYCIN; RECOMBINANT FOLLITROPIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; REPAGLINIDE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RILUZOLE; RIMEXOLONE; RISEDRONIC ACID; RITONAVIR; RITUXIMAB; RIVASTIGMINE; RIZATRIPTAN; ROFECOXIB; ROPINIROLE; ROSIGLITAZONE; SAQUINAVIR; SEVELAMER; SIBUTRAMINE; SILDENAFIL; STAVUDINE; TAMSULOSIN; TAZOROTENE; TELMISARTAN; TEMOZOLOMIDE; TENECTEPLASE; TETRAHYDROLIPSTATIN; TILUDRONIC ACID; TIROFIBAN; TIZANIDINE; TOLCAPONE; TOLTERODINE; TOPIRAMATE; TOPOTECAN; TOREMIFENE; TRANDOLAPRIL; TRASTUZUMAB; TRAVOPROST; TRIPTORELIN; UNCLASSIFIED DRUG; UNOPROSTONE ISOPROPYL ESTER; VALACICLOVIR; VALRUBICIN; VALSARTAN; ZAFIRLUKAST; ZALEPRON; ZANAMIVIR; ZOLEDRONIC ACID; ZOLMITRIPTAN;

CANADA; DRUG APPROVAL; DRUG MONITORING; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; UNITED STATES;

EID: 19444382975     PISSN: 02732300     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yrtph.2005.03.003     Document Type: Article

References (14)

1. Anon. Vioxx: lessons for Health Canada and the FDA Can. Med. Assoc. J. 172 2005 5
2. Center for Drug Evaluation and Research, 1996. Priority review policy. Manual of Policies and Procedures, MAPP 6020.3. Food and Drug Administration, Rockville, MD. URL: http://www.fda.gov/cder/mapp/6020-3.pdf (accessed: February 4, 2005)
3. Center for Drug Evaluation and Research, 2003. CDER 2003 Report to the nation: improving public health through human drugs. Food and Drug Administration, Rockville, MD. URL: http://www.fda.gov/cder/reports/rtn/2003/ rtn2003.pdf (accessed: February 4, 2005)
4. A.A. Daemmrich Pharmacopolitics: drug regulation in the United States and Germany 2004 University of North Carolina Press Chapel Hill, NC
5. Food and Drug Administration, 2002. FDA amends its regulations to provide for approval of certain new pharmaceutical products based on animal efficacy data. FDA, Rockville, MD. URL: http://www.fda.gov/bbs/topics/NEWS/2002/NEW00811. html (accessed: February 4, 2005)
6. Health Canada, 2004. Serving Canadians-now and into the future: strategic plan 2004-2007 for Health Canada's Health Products and Food Branch. Health Canada, Ottawa. URL: http://www.hc-sc.gc.ca/hpfb-dgpsa/strat_plan_e.pdf (accessed: February 4, 2005)
7. W. Kondro Drug approvals taking too long? Can. Med. Assoc. J. 166 2002 790
8. J.R. Landis, and G.G. Koch The measurement of observer agreement for categorical data Biometrics 33 1977 159 174
9. C.P. Milne, and E. Bergman Fast track product designation under the Food and Drug Administration Modernization Act: the industry experience Drug Inform. J. 35 2001 71 83
10. N.S.B. Rawson Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998 Can. Med. Assoc. J. 162 2000 501 504
11. N.S.B. Rawson Human resources for the approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States Can. J. Clin. Pharmacol. 9 2002 73 78
12. N.S.B. Rawson Timeliness of review and approval of new drugs in Canada from 1999 through 2001: is progress being made? Clin. Ther. 25 2003 1230 1247
13. N.S.B. Rawson, and K.I. Kaitin Canadian and US drug approval times and safety considerations Ann. Pharmacother. 37 2003 1403 1408
14. Therapeutic Products Directorate, 2002. Priority review of drug submissions (therapeutic products). Health Canada, Ottawa. URL: http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/prfactsheet2002_e.html (accessed: February 4, 2005)